# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frida Kahlo (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI011-SYN
- Date: 2026-10-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marisol Ortega, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-week review of function, mood, and the opioid taper. **S**

## History of present illness

Ms. Kahlo returns six weeks after her first visit and two weeks after her oxycodone was reduced to 52.5 MME a day. She has had no yawning, gooseflesh, stomach cramps, diarrhea, restlessness, or loss of sleep beyond her usual. Her pain has not worsened, and her PEG is 5.3, 27 percent below the 7.3 she scored at intake. With the shoe lift she now stands at the easel for 25 to 30 minutes at a time. She goes to physical therapy twice a week and to cognitive behavioral therapy weekly, and she has had no falls. She takes acetaminophen 1 g three times a day. She asks when the next reduction will be and wants it to stay slow. **S**

| Element | Detail |
|---|---|
| Taper | Two weeks at 52.5 MME a day; no withdrawal symptoms |
| PEG | 5.3, 27 percent below intake |
| Function | Stands 25 to 30 minutes at the easel with the shoe lift |
| Rehabilitation | Physical therapy twice weekly; cognitive behavioral therapy weekly |
| Safety | No falls; no sedation |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No sweats, chills, or sleep change |
| Gastrointestinal | Negative | No stomach cramps, diarrhea, nausea, or constipation |
| Musculoskeletal | Positive | Back, pelvic, and ankle pain, no worse since the reduction; no falls |
| Neurological | Positive | Burning in the right leg, less than at intake; no new weakness; no bladder or bowel control change |
| Psychiatric | Negative | Mood steady; PHQ-9 score 4 with item 9 scored 0; no anxiety or restlessness |

5 systems reviewed. **S**

## Current medications

- Oxycodone 10 mg oral tablet, one tablet three times daily as needed for pain **S**
- Oxycodone 5 mg oral tablet, one tablet at bedtime as needed for pain **S**
- Duloxetine 60 mg delayed-release oral capsule, one capsule daily **S**
- Acetaminophen 500 mg oral tablet, two tablets three times daily **S**
- Diclofenac sodium 1% topical gel, 2 g to the right ankle four times daily **S**
- Cholecalciferol (vitamin D3) 2,000 units oral tablet, one tablet daily **S**
- Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose; may repeat in the other nostril **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/70 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 50.5 kg; BMI 19.7 kg/m². All vital signs are synthetic.

ALT: 24 U/L; PEG pain and function score (0-10): 5.3; PHQ-9: 4. All results are synthetic.

## Change since baseline

- ALT: 22 U/L at baseline, 24 U/L at this visit **S**
- PEG pain and function score (0-10): 7.3 at baseline, 5.3 at this visit **S**
- PHQ-9: 8 at baseline, 4 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert and not sedated |
| Eyes | Pupils equal, normal in size, and reactive; no tearing |
| Skin | No sweating or gooseflesh |
| Back | Lumbar paraspinal tenderness, less than at intake |
| Right ankle | Bony enlargement and reduced motion; no effusion |
| Gait | Cane and shoe lift; steady |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Long-term opioid therapy on a gradual taper, 52.5 MME a day** (Z79.891). Two weeks after the first reduction she has no withdrawal and her function is better, so the first taper step met its goal. **S**
   - No change today.
   - Next reduction of about 10 percent in about two weeks, a month after the first, if pain and function hold.
   - Prescription drug monitoring program check before each prescription; repeat the urine drug test within a year of intake.
   - Naloxone stays at home.
2. **Chronic post-traumatic back and pelvic pain** (G89.21). PEG 5.3, a 27 percent improvement, just short of the 30 percent goal, which continues. PHQ-9 4. **S**
   - Continue duloxetine 60 mg daily, acetaminophen, physical therapy, and cognitive behavioral therapy.
3. **Post-traumatic osteoarthritis of the right ankle and foot** (M19.171). ALT 24 U/L on regular acetaminophen, little changed from 22. The standing goal is met, at 25 to 30 minutes with the shoe lift. **S**
   - Continue diclofenac gel and the shoe lift.
   - ALT again in about six months while she takes regular acetaminophen.
4. **Vitamin D deficiency** (E55.9). On repletion for six weeks. **S**
   - Recheck 25-hydroxyvitamin D in about seven weeks.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PEG pain, enjoyment of life, and general activity score | Every visit | Completed today | 5.3, 27 percent below intake; the 30 percent goal continues |
| Survey | PHQ-9 depression score, with item 9 | Every 2 to 4 weeks during active treatment | Completed today | 4, with item 9 scored 0 |
| Laboratory | ALT on regular acetaminophen | Periodically when acetaminophen approaches 3 g a day | Completed today | 24 U/L, normal |
| Medication safety | Opioid withdrawal symptoms | At each contact after a reduction | Completed today | None, here or at last week's visit |
| Medication safety | Opioid benefits and harms: function, sedation, constipation, falls | Every visit during a taper; at least every 3 months | Completed today | Function better; no sedation, constipation, or falls |
| Medication safety | Taper step | About 10 percent a month for long-term therapy, adjusted to her response | Up to date | Next step due in about two weeks |
| Medication safety | Prescription drug monitoring program check | Before each opioid prescription; at least every 3 months | Up to date | Checked at last week's visit: a single prescriber |
| Laboratory | Urine drug test, with consent | Before long-term therapy, then at least annually | Up to date | At intake; repeat within a year |
| Medication safety | Opioid use disorder assessment | Before tapering and whenever concerns arise | Up to date | No concerns since the assessment two weeks ago |
| Medication safety | Naloxone at home, with a family member trained | Offer when starting or continuing opioids; review each visit | Up to date | At home |
| Medication safety | Concurrent benzodiazepines or other sedatives | Every visit | Completed today | None |
| Examination | Fall risk | Every visit while on opioids and duloxetine | Up to date | Timed Up and Go 14 seconds last week; no falls |
| Examination | Right ankle examination: range of motion, effusion, alignment | Every visit | Completed today | Unchanged; no effusion |
| Imaging | Right ankle radiograph | Only for diagnostic uncertainty, clinical change, or surgical planning | Not indicated | No clinical change |
| Laboratory | CBC, creatinine, and blood pressure for chronic oral NSAID use | Every 6 to 12 months on oral NSAIDs | Not indicated | Topical diclofenac only |
| Self-management | Exercise and cognitive behavioral therapy adherence | Every visit | Completed today | Physical therapy twice weekly and cognitive behavioral therapy weekly |
| Laboratory | 25-hydroxyvitamin D | About 3 months after starting repletion | Due | Recheck in about seven weeks |

## Goal progress

- Improve the PEG score by at least 30% from baseline. Outcome by 2026-10-29: PEG fell from 7.3 to 5.3 by the six-week review, a 27% improvement; goal continued. **S**
- Stand at the easel for 30 minutes at a time by the six-week review. Outcome by 2026-10-29: Stands 25 to 30 minutes at the easel with the shoe lift. **S**
- First opioid dose reduction, agreed by the patient, without loss of function. Outcome by 2026-10-29: Reduced from 60 to 52.5 MME a day at the four-week visit; PEG and standing tolerance improved at the six-week review. **S**
- Naloxone in the home with a family member trained to use it. Outcome by 2026-09-17: Naloxone nasal spray dispensed; spouse taught at the first visit. **S**

## Guideline basis

- CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians (2017), American College of Physicians (Annals of Internal Medicine)
- VA/DoD Clinical Practice Guideline for the Diagnosis and Treatment of Low Back Pain (2022), U.S. Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, osteoarthritis and depression monographs (2026), Aether Forge

## Follow-up

- Chronic pain review in two weeks for the second taper step. **S**

